D/E 0.01 — less debt than most Healthcare peers (≈25th pctile)
P/E33.6xC+
P/E 33.6 — above the Healthcare median (≈75th pctile)
PEG0.87B+
PEG 0.87 — near fair value, classic Lynch benchmark (1.0)
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 82.2
Quality0.77
Growth0.94
Value0.76
Entry · Margin of safety
52-week rangeNear 52-week low
39% off the 12-month high
vs DCF fair value1% aboveest. fair value ~$188
Quality signals · context only
Gross profitability27% · Bgross profit ÷ total assets (Novy-Marx)
ROIC10.3% · Breturn on invested capital — not score-weighted
Why now
Veeva’s dominance in the life‑sciences cloud, anchored by its Vault CRM Suite and Data Cloud, fuels a relentless revenue engine that is expanding at 16.3% YoY while delivering $1.7B of free cash flow and a compelling 0.87 PEG ratio, proving the business is both growing and efficiently priced. The low‑debt balance sheet (D/E 0.01) and sub‑1× beta give investors upside with limited downside, making the current price a launchpad for a multi‑year compounding run. The thesis rests on the fact that Veeva’s integrated cloud stack locks in pharma and biotech customers, ensuring the growth engine stays hot.
Moat
Veeva’s Vault platform creates a high‑switching‑cost ecosystem: pharmaceutical and biotech firms embed Veeva’s CRM, content, and analytics tools across R&D, compliance, and commercial operations, making migration costly and time‑consuming. This lock‑in is reinforced by the company’s 28.4% profit margin, which reflects pricing power derived from its category‑leadership in regulated cloud solutions that rivals cannot replicate quickly.
Risk
The stock trades at a lofty 33.4 P/E, implying the market expects growth to accelerate even as revenue growth has slowed to a modest 16.3% YoY, raising the risk of a valuation correction if the pace falters. A beta of 0.94 signals sensitivity to broader market swings, and any loss of a major pharma client to a competing cloud provider would compress margins and erode the cash‑flow cushion. A sustained dip in revenue growth below 12% would trigger the bear case and invalidate the upside thesis.
Horizon
1-3 yr $244.59 (27-analyst consensus) — fundamentals + valuation re-rating. 5 yr $358.11 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $531.23 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · VEEV
$
%
%
Shares to buy
10
Position size
$1,897
3.8% of portfolio
Stop price
$142.27
25% below $189.70
$ at risk if stopped
$474.25
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Veeva Systems Inc. (VEEV): score, valuation & FAQ
Veeva Systems Inc. (VEEV) is a Health Information Services company that scores 82.2 out of 100 on the Bull Rankings quality-growth model — a strong reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are D/E (A-), Rev (B+) and PEG (B+). On valuation, VEEV sits close to our DCF fair-value estimate (within a few percent).
Is VEEV a good stock to buy?
Bull Rankings scores VEEV 82.2 out of 100 on its quality-growth model, which is a strong reading. That is driven by D/E (A-), Rev (B+) and PEG (B+). A score is a quantitative screen of Veeva Systems Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does VEEV score 82.2 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). VEEV earns its highest marks on D/E (A-), Rev (B+) and PEG (B+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is VEEV overvalued or undervalued?
Based on $189.70, VEEV sits close to our DCF fair-value estimate (within a few percent). It trades at a 33.6x× P/E (graded C+). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in VEEV?
The stock trades at a lofty 33.4 P/E, implying the market expects growth to accelerate even as revenue growth has slowed to a modest 16.3% YoY, raising the risk of a valuation correction if the pace falters. A beta of 0.94 signals sensitivity to broader market swings, and any loss of a major pharma client to a competing cloud provider would compress margins and erode the cash‑flow cushion. A sustained dip in revenue growth below 12% would trigger the bear case and invalidate the upside thesis.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.